Shengxiang Biotech announced that the company recently obtained EU CE IVDR certification for five products, including human papillomavirus nucleic acid typing test kits, etc. Two of these were Class C certified, and three were the company's first batch of products to obtain Class D certification in the highest risk category. This certification enriches the company's product line, indicates that it conforms to strict international standards, and is one of the important achievements of the company's strategy. However, the future performance of approved products is affected by various factors, and the specific impact on the company's performance cannot yet be predicted.

Shengxiang Biotech announced that the company recently obtained EU CE IVDR certification for five products, including human papillomavirus nucleic acid typing test kits, etc. Two of these were Class C certified, and three were the company's first batch of products to obtain Class D certification in the highest risk category. This certification enriches the company's product line, indicates that it conforms to strict international standards, and is one of the important achievements of the company's strategy. However, the future performance of approved products is affected by various factors, and the specific impact on the company's performance cannot yet be predicted.